Abstract
A systematic review relating to bladder cancer epidemiology, risk factors and occupational hazards was conducted. This was to identify the bladder cancer epidemiology and risk factors in muscle invasive disease. The search strategy aimed to identify all references related to bladder cancer AND screening. Search terms used were as follows: (Bladder cancer) AND (Immune checkpoint inhibitors). The following databases were screened from 1989 to June 2020:
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Moher D, Liberati A, Tetzlaff J, Altman DG. “Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The Prisma Statement.” [In English]. BMJ (Online) 339, no. 7716 (08 Aug 2009):332–36.
Mays N, Pope C, Popay J. “Systematically Reviewing Qualitative and Quantitative Evidence to Inform Management and Policy-Making in the Health Field.” [In English]. Journal of Health Services Research and Policy 10, no. SUPPL. 1 (July 2005):6–20.
Massard C, Gordon MS, Sharma S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder Cancer. J Clin Oncol. 2016;34(26):3119–25.
Schwamborn K, Ammann JU, Knüchel R, et al. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays. Virchows Arch. 2019;475(5):599–608.
Zavalishina L, Tsimafeyeu I, Povilaitite P, et al. RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer. Virchows Arch. 2018;473(6):719–24.
Tretiakova M, Fulton R, Kocherginsky M, et al. Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression. Mod Pathol. 2018;31(4):623–32.
de Jong JJ, Stoop H, Nieboer D, Boormans JL, van Leenders GJLH. Concordance of PD-L1 expression in matched urothelial bladder cancer specimens. Histopathology. 2018;73(6):983–9.
Wang B, Pan W, Yang M, et al. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder. Cancer Sci. 2019;110(2):489–98.
Burgess EF, Livasy C, Hartman A, et al. Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions. Urol Oncol. 2019;37(5):299.e19–25.
Pichler R, Fritz J, Lackner F, et al. Prognostic value of testing PD-L1 expression after radical cystectomy in high-risk patients. Clin Genitourin Cancer. 2018;16(5):e1015–24.
Levy A, Massard C, Soria JC, Deutsch E. Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: single centre subset analysis from a phase 1/2 trial. Eur J Cancer. 2016;68:156–62.
Reis H, Serrette R, Posada J, et al. PD-L1 expression in urothelial carcinoma with predominant or pure variant histology: concordance among 3 commonly used and commercially available antibodies. Am J Surg Pathol. 2019;43(7):920–7.
Davick JJ, Frierson HF, Smolkin M, Gru AA. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases. Hum Pathol. 2018;81:184–91.
Petrylak DP, de Wit R, Chi KN, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet. 2017;390(10109):2266–77.
Yang M, Yu Q, Liu J, et al. T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: clinicopathologic correlations and association with survival. J Surg Oncol. 2015;112(4):430–5.
Segovia C, San José-Enériz E, Munera-Maravilla E, et al. Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression. Nat Med. 2019;25(7):1073–81.
Borcoman E, De La Rochere P, Richer W, et al. Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer. Onco Targets Ther. 2019;8(5):e1581556.
Leko V, McDuffie LA, Zheng Z, et al. Identification of neoantigen-reactive tumor-infiltrating lymphocytes in primary bladder cancer. J Immunol. 2019;202(12):3458–67.
Szabados B, van Dijk N, Tang YZ, et al. Response rate to chemotherapy after immune checkpoint inhibition in metastatic Urothelial Cancer. Eur Urol. 2018;73(2):149–52.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2021 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Goonewardene, S.S., Ventii, K., Bahl, A., Persad, R., Motiwala, H., Albala, D. (2021). The Role of Immune Checkpoint Inhibitors in Bladder Cancer. In: Management of Muscle Invasive Bladder Cancer. Management of Urology. Springer, Cham. https://doi.org/10.1007/978-3-030-57915-9_65
Download citation
DOI: https://doi.org/10.1007/978-3-030-57915-9_65
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-57914-2
Online ISBN: 978-3-030-57915-9
eBook Packages: MedicineMedicine (R0)